Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Travere Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 98.6%. For fiscal 2026 it was 97.9%, against 96.7% the year before. The highest annual figure on record is 98.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | 97.9% | +1.2 |
| FY2025 | Dec 31, 2024 | 96.7% | +4.6 |
| FY2024 | Dec 31, 2023 | 92.1% | −3.8 |
| FY2023 | Dec 31, 2022 | 96.0% | −1.1 |
| FY2022 | Dec 31, 2021 | 97.1% | +0.2 |
| FY2021 | Dec 31, 2020 | 96.9% | −0.1 |
| FY2020 | Dec 31, 2019 | 97.0% | +0.4 |
| FY2019 | Dec 31, 2018 | 96.6% | −1.0 |
| FY2018 | Dec 31, 2017 | 97.7% | +1.1 |
| FY2017 | Dec 31, 2016 | 96.6% | −1.2 |
| FY2016 | Dec 31, 2015 | 97.8% | −0.2 |
| FY2015 | Dec 31, 2014 | 98.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | 98.7% | +0.0 |
| Q1 FY2027 | Mar 31, 2026 | 98.5% | +4.2 |
| Q4 FY2026 | Dec 31, 2025 | 98.0% | +1.4 |
| Q3 FY2026 | Sep 30, 2025 | 99.0% | +1.6 |
| Q2 FY2026 | Jun 30, 2025 | 98.7% | +2.5 |
| Q1 FY2026 | Mar 31, 2025 | 94.3% | −2.1 |
| Q4 FY2025 | Dec 31, 2024 | 96.6% | +6.7 |
| Q3 FY2025 | Sep 30, 2024 | 97.4% | +0.9 |
| Q2 FY2025 | Jun 30, 2024 | 96.2% | +0.7 |
| Q1 FY2025 | Mar 31, 2024 | 96.4% | +9.8 |
| Q4 FY2024 | Dec 31, 2023 | 89.9% | −7.2 |
| Q3 FY2024 | Sep 30, 2023 | 96.5% | +0.5 |
| Q2 FY2024 | Jun 30, 2023 | 95.5% | +2.7 |
| Q1 FY2024 | Mar 31, 2023 | 86.6% | −4.3 |
| Q4 FY2023 | Dec 31, 2022 | 97.0% | +0.4 |
| Q3 FY2023 | Sep 30, 2022 | 96.0% | −1.6 |
| Q2 FY2023 | Jun 30, 2022 | 92.8% | −4.1 |
| Q1 FY2023 | Mar 31, 2022 | 90.9% | −5.7 |
| Q4 FY2022 | Dec 31, 2021 | 96.7% | +0.8 |
| Q3 FY2022 | Sep 30, 2021 | 97.7% | −0.0 |
| Q2 FY2022 | Jun 30, 2021 | 97.0% | +0.1 |
| Q1 FY2022 | Mar 31, 2021 | 96.5% | −0.6 |
| Q4 FY2021 | Dec 31, 2020 | 95.9% | −0.4 |
| Q3 FY2021 | Sep 30, 2020 | 97.7% | +1.1 |
| Q2 FY2021 | Jun 30, 2020 | 96.9% | −0.9 |
| Q1 FY2021 | Mar 31, 2020 | 97.1% | −0.3 |
| Q4 FY2020 | Dec 31, 2019 | 96.3% | −0.0 |
| Q3 FY2020 | Sep 30, 2019 | 96.6% | −0.6 |
| Q2 FY2020 | Jun 30, 2019 | 97.8% | +0.7 |
| Q1 FY2020 | Mar 31, 2019 | 97.4% | +1.6 |
| Q4 FY2019 | Dec 31, 2018 | 96.3% | −0.9 |
| Q3 FY2019 | Sep 30, 2018 | 97.2% | −0.5 |
| Q2 FY2019 | Jun 30, 2018 | 97.2% | −0.8 |
| Q1 FY2019 | Mar 31, 2018 | 95.8% | −2.1 |
| Q4 FY2018 | Dec 31, 2017 | 97.2% | +0.4 |
| Q3 FY2018 | Sep 30, 2017 | 97.7% | +2.3 |
| Q2 FY2018 | Jun 30, 2017 | 97.9% | – |
| Q1 FY2018 | Mar 31, 2017 | 97.9% | – |
| Q4 FY2017 | Dec 31, 2016 | 96.8% | – |
| Q3 FY2017 | Sep 30, 2016 | 95.4% | – |
See a number that looks wrong?